These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 30135241)

  • 1. Accurate Estimation of In Vivo Inhibition Constants of Inhibitors and Fraction Metabolized of Substrates with Physiologically Based Pharmacokinetic Drug-Drug Interaction Models Incorporating Parent Drugs and Metabolites of Substrates with Cluster Newton Method.
    Yoshida K; Maeda K; Konagaya A; Kusuhara H
    Drug Metab Dispos; 2018 Nov; 46(11):1805-1816. PubMed ID: 30135241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Trial Data-Driven Risk Assessment of Drug-Drug Interactions: A Rapid and Accurate Decision-Making Tool.
    Yuan T; Bi F; Hu K; Zhu Y; Lin Y; Yang J
    Clin Pharmacokinet; 2024 Aug; 63(8):1147-1165. PubMed ID: 39102093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a Physiologically Based Pharmacokinetic Model for Quantitative Prediction of Drug-Drug Interactions via CYP3A4 and Estimation of the Intestinal Availability of CYP3A4 Substrates.
    Mano Y; Sugiyama Y; Ito K
    J Pharm Sci; 2015 Sep; 104(9):3183-93. PubMed ID: 26045365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.
    Min JS; Bae SK
    Arch Pharm Res; 2017 Dec; 40(12):1356-1379. PubMed ID: 29079968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
    Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
    Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions.
    Feng B; Varma MV
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S110-21. PubMed ID: 27385169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model.
    Xue C; Zhang X; Cai W
    Pharmaceutics; 2017 Dec; 10(1):. PubMed ID: 29267251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone.
    Chen Y; Mao J; Hop CE
    Drug Metab Dispos; 2015 Feb; 43(2):182-9. PubMed ID: 25324279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans.
    Min JS; Kim D; Park JB; Heo H; Bae SH; Seo JH; Oh E; Bae SK
    Drug Des Devel Ther; 2016; 10():2959-2972. PubMed ID: 27695293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of Prediction Methods for Drug-Drug Interactions Based on the Construction of Physiologically Based Pharmacokinetic Models for Hepatic OATP Substrate Drugs and Endogenous Substrates].
    Yoshikado T
    Yakugaku Zasshi; 2023; 143(1):11-19. PubMed ID: 36596534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models.
    Yoshikado T; Maeda K; Kusuhara H; Furihata KI; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2739-2750. PubMed ID: 28495568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction.
    Chen Y; Ma F; Lu T; Budha N; Jin JY; Kenny JR; Wong H; Hop CE; Mao J
    Clin Pharmacokinet; 2016 Jun; 55(6):735-49. PubMed ID: 26692192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically-based pharmacokinetic modeling to evaluate in vitro-to-in vivo extrapolation for intestinal P-glycoprotein inhibition.
    Yamazaki S; Evers R; De Zwart L
    CPT Pharmacometrics Syst Pharmacol; 2022 Jan; 11(1):55-67. PubMed ID: 34668334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From preclinical to human--prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example.
    Sinha VK; Snoeys J; Osselaer NV; Peer AV; Mackie C; Heald D
    Biopharm Drug Dispos; 2012 Mar; 33(2):111-21. PubMed ID: 22383166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Analysis of Complex Drug-Drug Interactions between Cerivastatin and Metabolism/Transport Inhibitors Using Physiologically Based Pharmacokinetic Modeling.
    Yao Y; Toshimoto K; Kim SJ; Yoshikado T; Sugiyama Y
    Drug Metab Dispos; 2018 Jul; 46(7):924-933. PubMed ID: 29712725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis.
    Hanke N; Teifel M; Moj D; Wojtyniak JG; Britz H; Aicher B; Sindermann H; Ammer N; Lehr T
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):291-304. PubMed ID: 29204687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extrapolating in vitro metabolic interactions to isolated perfused liver: predictions of metabolic interactions between R-bufuralol, bunitrolol, and debrisoquine.
    Haddad S; Poulin P; Funk C
    J Pharm Sci; 2010 Oct; 99(10):4406-26. PubMed ID: 20310018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of clearance concepts and modeling techniques in the prediction of metabolic drug-drug interactions.
    Ito K; Sugiyama Y
    Trends Pharmacol Sci; 2010 Aug; 31(8):351-5. PubMed ID: 20542578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simulations of Cytochrome P450 3A4-Mediated Drug-Drug Interactions by Simple Two-Compartment Model-Assisted Static Method.
    Iga K; Kiriyama A
    J Pharm Sci; 2017 May; 106(5):1426-1438. PubMed ID: 28089686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.